Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it has entered into a ...

Updated Fly-In Program outlines virtual consultations, travel timelines, recovery planning, and follow-up care for out-of-town patients visiting Tampa, Florida. TAMPA, FLORIDA / ACCESS Newswire / ...

Ikonisys SA (Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancers through a ...

The "Vegetarian Softgel Capsules Market - Global Forecast 2025-2032" report has been added to ResearchAndMarkets.com's offering.The vegetarian softgel capsules market is entering a critical phase of ...

A closer look at the artistry, technique, and philosophy behind Dr. Jindal's most sought-after transformation. TORONTO, ON / ACCESS Newswire / December 19, 2025 / Many patients don't realize how far ...

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether ...

Comprehensive submission package includes evidence of substantially improved survival among adrabetadex-treated patients with infantile-onset Niemann Pick disease type C (NPC), intended to serve as a ...

Premier Investment Firm Adds Physician-Scientist and Drug Developer to Further Advance Its Therapeutics and Life Sciences StrategyAUSTIN, Texas--(BUSINESS WIRE)--Breyer Capital, a premier venture ...

D-printed prosthesis from America's No. 1 digital dental lab offers streamlined delivery and predictable outcome. NEWPORT BEACH, CALIFORNIA / ACCESS Newswire / December 19, 2025 / Glidewell has ...

MESA, AZ / ACCESS Newswire / December 19, 2025 / Medical Care Technologies, Inc. (OTC PINK:MDCE) today announced that its first-ever AI-powered mobile application has entered final review stages on ...

A new, highly accurate testing service that improves the early-stage detection of bowel cancer with strong clinical validity will be available in the UK within the next few weeks.The service increases ...

Guselkumab has received approval for moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy.1The decision is supported by the ...